Home » Stocks » IMMP

Immutep Limited (IMMP)

Stock Price: $3.20 USD -0.12 (-3.61%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $3.16 -0.04 (-1.25%) Jan 22, 4:20 PM
Market Cap 205.29M
Revenue (ttm) 11.38M
Net Income (ttm) -9.29M
Shares Out 338.86M
EPS (ttm) -0.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $3.20
Previous Close $3.32
Change ($) -0.12
Change (%) -3.61%
Day's Open 3.10
Day's Range 3.05 - 3.24
Day's Volume 709,962
52-Week Range 0.67 - 5.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 22 hours ago

Highlights

GlobeNewsWire - 23 hours ago

Immutep's Collaboration and Exclusive License with GSK Remains in Place Immutep's Collaboration and Exclusive License with GSK Remains in Place

GlobeNewsWire - 2 weeks ago

Sydney, AUSTRALIA, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseas...

GlobeNewsWire - 3 weeks ago

Sydney, AUSTRALIA, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments fo...

GuruFocus - 3 weeks ago

Breast cancer is the second leading cause of death of women in the U.S. alone. Given the prevalence of the disease, it's no surprise that numerous pharmaceutical and biotech companies are sear...

Other stocks mentioned: GLSI, SLS
Seeking Alpha - 1 month ago

JD Health of Guangzhou, the online health-care arm of China e-commerce giant JD.com, completed a $3.5 billion Hong Kong IPO and rose 56% in its first trading session. Beijing's Sinovac Biotech...

Other stocks mentioned: IVBXF, JD, SBHMY, SVA
InvestorPlace - 1 month ago

Shares of IMMP stock are taking off on Thursday after the firm's China-based partner announced a new breast cancer treatment trial in 2021. The post IMMP Stock: Why Immutep Stock Is Up 225% So...

Benzinga - 1 month ago

Immutep (NASDAQ: IMMP) shares are trading higher on Thursday after the company reported a statistically significant survival benefit for key patient groups in its ongoing Phase IIb AIPAC study...

Other stocks mentioned: GLSI, THC
Market Watch - 1 month ago

Shares of Immumetp Ltd., an Australian biotech with a Nasdaq listing, soared 190% Thursday, after the company reported positive results from a trial of a treatment for metastatic breast cancer.

GlobeNewsWire - 1 month ago

Sydney, AUSTRALIA, Dec. 10, 2020 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disea...

GlobeNewsWire - 1 month ago

Sydney, AUSTRALIA, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseas...

GlobeNewsWire - 2 months ago

SYDNEY, Australia, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces it is advancing clinical development for its lead product candidate eftilagimod alpha (“...

GlobeNewsWire - 2 months ago

Sydney, Australia, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) : Australian biotechnology company Immutep Limited (“Immutep“ or the “Company“), which is listed ...

GlobeNewsWire - 2 months ago

Sydney, Australia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- ASX/Media Release                                                                                                                    

GlobeNewsWire - 2 months ago

SYDNEY, Australia, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments fo...

GlobeNewsWire - 2 months ago

SYDNEY, Australia, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disea...

GlobeNewsWire - 2 months ago

SYDNEY, Australia, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce it has signed a Material Transfer Agreement (...

GlobeNewsWire - 3 months ago

SYDNEY, Australia, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseas...

GlobeNewsWire - 3 months ago

SYDNEY, Australia, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments fo...

GlobeNewsWire - 3 months ago

SYDNEY, Australia, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments fo...

GlobeNewsWire - 4 months ago

SYDNEY, Australia, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces new interim data from its ongoing Phase II TACTI-002 study. The data was presented in...

GlobeNewsWire - 4 months ago

SYDNEY, Australia, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to report further interim data from its ongoing INSIGHT-004 Phase I clinical trial. ...

GlobeNewsWire - 4 months ago

SYDNEY, Australia, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to announce that the Australian Research Council (ARC) has awarded Immutep and resear...

GlobeNewsWire - 4 months ago

SYDNEY, Australia, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments ...

GlobeNewsWire - 5 months ago

SYDNEY, Australia, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments ...

GlobeNewsWire - 6 months ago

SYDNEY, Australia, July 15, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces the grant of patent no. 10,711,060 entitled “Antibody mol...

GlobeNewsWire - 6 months ago

SYDNEY, Australia, June 29, 2020 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments...

GlobeNewsWire - 7 months ago

SYDNEY, Australia, June 22, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,437,826 cash reb...

GlobeNewsWire - 7 months ago

Presented at ASCO 2020 Annual Meeting

GlobeNewsWire - 7 months ago

SYDNEY, Australia, June 01, 2020 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to report first interim data from its ongoing INSIGHT-004 Phase I clinical trial. Th...

GlobeNewsWire - 7 months ago

SYDNEY, Australia, May 29, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments f...

GlobeNewsWire - 9 months ago

SYDNEY, Australia, April 22, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments...

GlobeNewsWire - 9 months ago

SYDNEY, Australia, April 16, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce that Batavia Biosciences, its manufacturin...

GlobeNewsWire - 9 months ago

SYDNEY, Australia, April 08, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to inform that EOC Pharma (“EOC”) and Immutep jointly ...

GlobeNewsWire - 9 months ago

SYDNEY, Australia, March 24, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunother...

GlobeNewsWire - 10 months ago

SYDNEY, Australia, March 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to report that it has been informed its Chinese partne...

GlobeNewsWire - 10 months ago

SYDNEY, Australia, March 09, 2020 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatment...

GlobeNewsWire - 11 months ago

SYDNEY, Australia, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments ...

GlobeNewsWire - 11 months ago

SYDNEY, Australia, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments ...

GlobeNewsWire - 1 year ago

SYDNEY, Australia, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments ...

Seeking Alpha - 1 year ago

Near-Term Upside In LAG-3 Immunotherapy - Buy Immutep

GlobeNewsWire - 1 year ago

SYDNEY, Australia, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments ...

GlobeNewsWire - 1 year ago

SYDNEY, Australia, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the grant of patent no. 3116909 entitled “An...

GlobeNewsWire - 1 year ago

SYDNEY, Australia, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments ...

GlobeNewsWire - 1 year ago

Key Trial Findings

GlobeNewsWire - 1 year ago

SYDNEY, Australia, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments ...

GlobeNewsWire - 1 year ago

SYDNEY, Australia, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments ...

GlobeNewsWire - 1 year ago

SYDNEY, Australia, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or the “Company”), a biotechnology company developing novel immunotherapy treatments...

GlobeNewsWire - 1 year ago

SYDNEY, Australia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the grant of patent no. 6576962 entitled “A...

GlobeNewsWire - 1 year ago

SYDNEY, Australia, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments ...

About IMMP

Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ?eftilagimod alpha' or ?efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evalu... [Read more...]

Industry
Biotechnology
CEO
Marc Voigt
Stock Exchange
NASDAQ
Ticker Symbol
IMMP
Full Company Profile

Financial Performance

In 2020, Immutep's revenue was 16.50 million, an increase of 120.31% compared to the previous year's 7.49 million. Losses were -13.47 million, -26.58% less than in 2019.

Financial numbers in millions AUD.
Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Immutep stock is "Buy." The 12-month stock price forecast is 6.01, which is an increase of 87.81% from the latest price.

Price Target
$6.01
(87.81% upside)
Analyst Consensus: Buy